Compound	Average M concentration required to depolarize to 45 mV	Equipotent $M$ ratio
Acetylcholine Acetylthiolcholine Acetylthionocholine	$5 \times 10^{-6}$ $5 \times 10^{-5}$ $5 \times 10^{-6}$	$1 \\ 17 \\ 1.7$

enzyme formed during the hydrolysis of either AcCh or AcSCh.

Electric eel acetylcholinesterase was used for these studies. The  $K_{\rm m}$  of the thiono ester was found to be  $6 \times 10^{-4} M$ , compared with a  $K_{\rm m}$  of  $1 \times 10^{-4}$  for AcCh and  $0.6 \times 10^{-4}$  for AcSCh. The  $V_{\rm max}$  of the hydrolysis of acetylthionocholine was significantly lower than that of AcCh or AcSCh.

## **Experimental Section**

Acetylthionocholine Bromide.—Na (200 mg) was dissolved in 5.0 g of 2-dimethylaminoethanol, followed by the addition of a solution of 8.0 g of ethyl thionoacetate<sup>18</sup> in 100 ml of toluene. A slow stream of N<sub>2</sub> was passed into the mixture which was heated at 97–98° for 2 hr. The reaction mixture was concentrated *in vacuo* in a 50° bath. The residue was acidified with 5 ml of concentrated HCl in 70 ml of ice-cold H<sub>2</sub>O and the mixture was filtered. The filtrate was extracted with 200 ml of Et<sub>2</sub>O to remove unreacted ethyl thionoacetate. The aqueous layer was shaken with 35 ml of ice-cold saturated Na<sub>2</sub>CO<sub>3</sub>, followed by extraction with 40-ml portions of Et<sub>2</sub>O. The organic extracts were washed with H<sub>2</sub>O and dried (Mg<sub>2</sub>SO<sub>4</sub>). Addition of 2.0 ml of MeBr to the Et<sub>2</sub>O led, after refrigeration, to the formation

(18) U. Schmidt, E. Heymann, and K. Kabitzke, Chem. Ber., 96, 1478 (1963).

of 2.4 g of light yellow crystals. The product was recrystallized from 2:1 Me<sub>2</sub>CO-EtOH; mp 151-152°;<sup>19</sup> uv  $\lambda_{max}$  (EtOH) 237 m $\mu$  ( $\epsilon_{m x}$  8440).

Anal. ( $C_{7}H_{10}BrNOS$ ) C, 34.71; H, 6.65; S, 13.23. Found: C, 34.81; H, 6.68; S, 12.82.

Acetylthionothiolcholine Bromide.—This compound was obtained in 20% yield by the reaction of 6.0 g of 2-dimethylaminoethanethiol and 8.0 g of ethyl thionoacetate in toluene followed by quaternization with MeBr. After three recrystallizations from EtOH the product melted at 169°; uv (EtOH)  $\lambda_{max}$  298 m $\mu$  ( $\epsilon_{max}$  7830).

Anal. (C7H16BrNS2) C, H, S.

**Depolarizing Activity.**—The depolarizing activity of acetylthionocholine was measured in the isolated single cell electroplax preparation, using cells from the electric organ of *E. electricus.*<sup>20,21</sup> Eserine was added to prevent hydrolysis by acetylcholinesterase present in the tissue.

Hydrolysis by Acetylcholinesterase.—Highly purified electric eel acetylcholinesterase was used for these studies. Enzyme assays were carried out titrimetrically, using a Radiometer auto-titrator. A constant pH of  $7.5 \pm 0.02$  was maintained during enzymatic hydrolysis by the automatic addition of 0.01 N NaOH to neutralize the acetic acid produced by substrate hydrolysis. Initial rates were used, the rate being constant for at least 2 min.

Acknowledgments.—We are indebted to Mrs. Eva Bartels of Columbia University for the electroplax assays and to Professor David Nachmansohn of Columbia University for a gift of the acetylcholinesterase used in these studies. This work was supported by grants from the National Science Foundation (GB-6835) and the National Institute for Neurological Diseases (NB-07835).

(19) The melting point was determined with a Gallenkamp melting point apparatus and has been corrected.

(21) H. B. Higman and E. Bartels, ibid., 54, 543 (1962).

# In Vitro Inhibition of Cholesterolgenesis by Various Thyroid Hormone Analogs

C. D. ESKELSON, C. R. CAZEE, W. ANTHONY, J. C. TOWNE, AND B. R. WALSKE

Radioisotope Service, Veterans Administration Hospital, Tucson, Arizona 85713

## Received July 17, 1969

Nineteen thyroid hormone analogs were tested in an *in vitro* cholesterolgenic liver homogenate system obtained from rats. <sup>14</sup>C-Acetate was used as substrate, DMSO was used as a solvent for adding the thyroid hormone analogs to the system. Of those compounds tested, L-triiodothyronine, D-thyroxine, DL-triiodothyronine, and DL-3,5-diiodo-3'-phenylthyronine at  $1.0 \times 10^{-4} M$  inhibited cholesterolgenesis from <sup>14</sup>C-acetate substrate. No effect was elicited by T<sub>3</sub> or T<sub>4</sub> when mevalonate was substrate. These studies indicated that the 3'-I or a bulky 3'-Ph associated with either D- or L-thyronine is necessary for inhibition of *in vitro* cholesterolgenesis. The D isomer is more active than the L isomer in this system. The need for higher than physiological levels of the thyroid hormones (triiodothyronine or thyroxine) in this system is in part a result of the nonspecific binding of the hormones to inert proteins in the homogenate system. When enough hormone is present to saturate the binding sites on the inert proteins the remaining hormone binds to active proteins contained in the microsomes resulting in an inhibition of cholesterolgenesis.

The alteration of blood cholesterol concentrations associated with thyroid function is well known. The hypocholesterolemia associated with thyroxine administration is attributed in part to an increased conversion of cholesterol into bile acids which overrides the increased cholesterolgenesis caused by thyroxine.<sup>1</sup> In thyroidectomized animals a decrease in the level of  $\beta$ -hydroxy- $\beta$ -methylglutaryl-coenzyme A reductase (HMG-reductase) occurs whereas the administration of thyroxine increases the levels of HMG-reductase re-

(1) D. Kritchevsky, Metabolism, 9, 984 (1964).

sulting in increased cholesterolgenesis.<sup>2,3</sup> In addition to the studies above, a new parameter was recently reported in which the addition of L-triiodothyronine ( $T_3$ ) and L-thyroxine ( $T_4$ ) to an *in vitro* cholesterolgenic rat liver homogenate from euthyroid rats resulted in decreased cholesterolgenesis.<sup>4</sup> The studies presented here are an extension of those studies and indicate that a structural specificity similar to that of  $T_3$  and  $T_4$  is

(2) W. Gruder, I. Nolte, and O. Wieland, Eur. J. Biochem., 4, 273 (1968).

<sup>(20)</sup> E. Schoeffeniels, Biochim. Biophys. Acta, 26, 585 (1957).

<sup>(3)</sup> F. A. Gries, F. Matschinsky, and O. Wieland, *Biochim. Biophys. Acta*, **56**, 615 (1962).

<sup>(4)</sup> C. D. Eskelson, Life Sci., 467 (1968).

generally necessary for the decreased cholesterolgenic response. Evidence is presented indicating that the hormone response resides primarily in the microsomes and that the response occurs only after all the  $T_3$  or  $T_4$ binding sites on the soluble proteins and most of the binding sites on microsomal proteins are satisfied.

#### Methods

The methods have been described earlier<sup>4</sup> and consist of a broken cell preparation of liver containing only microsomes and the soluble cellular fraction prepared with modification according to the procedure of Bucher and McGarrahan.<sup>5</sup> Either <sup>14</sup>C-acetate or <sup>14</sup>C-mevalonate was employed as substrate. Cofactors and pH 7.0 phosphate buffer described by Knauss, et al.,<sup>6</sup> were also added to the enzymic system. All of the thyroid analogs were added to the system in 0.2 ml of DMSO. The final total volume of the system was adjusted to 5.0 ml and incubated for 1 hr in a water bath maintained at 37°. The *de noro* synthesized cholesterol was isolated from the system by extraction with petroleum ether and precipitation with tomatine. The radiometric determination was made according to the procedure of Kabara, et al.<sup>7</sup>

The disintegration rate/min (dpm), mean, standard deviation (std dev), and student "t" tests between means were computed by an IBM 1620 computer. The tabular and graphical representations are expressed as the average of four determinations  $\pm$  the standard deviation. Only *P* values equal to or greater than 98% level were accepted as significant.

Many of the enzyme preparations used in these studies were stored up to 7 weeks at Dry Ice temperatures which does not alter enzymic activity in this system.<sup>5</sup>

#### **Experimental Section**

 $T_3$  and  $T_4$  Binding Studies.--The binding of  $T_3$  and  $T_4$  to the proteins and microsomes in the enzymic system was determined in the regular incubation mixture containing nonradioactive acetate substrate.

The thyroid hormones were added to the liver homogenate system at  $1.0 \times 10^{-3}$ ,  $1.0 \times 10^{-3}$ , and  $1.0 \times 10^{-5}$  M, with a final T<sub>4</sub> concentration of  $4.4 \times 10^{-8}$  M and a final T<sub>3</sub> concentration of  $4 \times 10^{-9}$  M. There were 5.86 µCi of radioactive T<sub>4</sub> and 5.68 µCi of radioactive T<sub>3</sub> in the respective flasks.

The studies were done in duplicate by incubating the enzymic system containing the various concentrations of hormones for 1 hr. Each flask's contents was cooled to ice temperatures and then transferred to individual centrifuge tubes by rinsing with 6 ul of 3:1 H<sub>2</sub>O solution-pH 7.0 buffer. The solution was centrifuged at 0°, 104,000g for 30 min and the supernataut was poured off and diluted to 15 nd with H<sub>2</sub>O. The supernatant was allowed to drain for 10 min from the microsome button in the bottom of the centrifuge tube. The microsomes were then dissolved in 2 ml of 5 N NaOH. This solution (1 ml) was counted in a well-type scintillation counter as was 1 ml of the diluted supernataur. To 1 ml of the diluted supernatant was added 2 nil of 0.6 N HClO<sub>4</sub> and the protein button obtained by centrifugation. The excess supernatant fluid was allowed to drain from the protein button for 3 min. The radioactivity in the protein button was determined by means of a well-type scintillation counter. The values in Figures 3 and 4 are expressed as

the per cent of the total radioactive  $T_{\lambda}$  or  $T_4$  added to the enzymic system.

Determination of Thyroid Hormone Site of Action .--- To deterunite the site of action of the thyroid hormones in this system <sup>14</sup>C-acetate was used as substrate. The experiment was conducted using nine groups. The enzyme pool (liver homogenate) was divided into three equal volumes. To the control enzyme pool was added 0.1 ml of DMSO ml of enzyme solution. the second enzyme pool was added 0.1 ml of DMSO, nd of enzyme solution and containing enough 1.-T<sub>a</sub> so that the final concentration in the enzyme mixture is  $2.5 \times 10^{-4}$  M. To the third euzyme pool was added 0.1 ml of DMSO ml of eozyme solution and containing enough  $1-T_4$  so that the final concentration in the euzyme mixture is  $2.5 \times 10^{-4} M$ . These euzymic pools were then incubated for 15 min at 37° and then rapidly cooled to 5°. The microsomes and soluble proteins were next separated from each pool by centrifugation at 0° and at 104,000g. The microsomes from 60 ml each of the pretreated homogenate were resuspended in 20 ml of a 50:50 dilution (pH 7.0) phosphate incubation buffer with H<sub>2</sub>O. Crossover studies using microsomes (M) which were pretreated with DMSO, those pretreated with  $1-T_4(M_{T_4})$ , and those pretreated with  $\iota_{2}T_{3}(M_{T_{3}})$  were done by adding the various soluble enzymes which were obtained from the pretreated enzymic pool, *i.e.*, those soluble enzymes (E) that were pretreated with DMSO, with 1  $T_4(E_{T_4})$ , and with 1  $T_3(E_{T_4})$ . The first group which served as the control group contained tere samples. The remaining groups each consisted of four samples. To the samples of the first, second, and third groups was added 1 ul of the microsonial suspension from the enzymic preparation pretreated with DMSO.

To the samples of the first, second, and third groups was added 2 ml of the erzyme solutions which were pretreated with DMSO,  $t_2T_3$ , and  $t_2T_4$ , respectively. To all of the samples of groups 4, 5, and 6 was added 4 ml of microsomal suspension obtained from the erzymic pool pretreated with  $t_2T_3$ . To the samples of the fourth, fifth, and sixth groups was added 2 ml of enzyme solutions which were pretreated with  $t_2T_3$ ,  $t_2T_4$ , and DMSO, respectively. To all of the samples of groups 7, 8, and 9 was added 4 ml of microsomal solution obtained from the enzyme solutions which were pretreated with  $t_2T_3$ ,  $t_2T_4$ , and DMSO, respectively. To all of the samples of groups 7, 8, and 9 was added 4 ml of microsomal solution obtained from the enzymic pool pretreated with  $t_2T_4$ . To the samples of the seventh, eighth, and minth groups was added 2 ml of enzyme solutions which were pretreated with  $t_2T_4$ ,  $t_3$ ,  $t_4T_4$ , and DMSO, respectively. The results are expressed as described earlier (see Table IV).

#### Results

The decreased rate of cholesterolgenesis by  $T_3$  is illustrated in Figure 1. The complete system using acetate as substrate with DMSO added as a control proceeds with a linear rate, after a 15-min lag. It is believed that the lag is due to the equilibration of the system to substrates, temperature, etc.  $T_3$  added at  $1.0 \times 10^{-4}$  M depresses the rate of cholesterol synthesis to about 50% of its normal rate. No inhibition is observed in the cholesterol biosynthesis system with  $T_5$ when mevalonate is used as substrate (Table I).

The inhibition of cholesterolgenesis from acetate by  $T_3$  is proportional to the added  $T_3$  concentration. Figure 2 depicts the sensitivity of  $T_3$ 's inhibition as beginning at the level of  $2.5 \times 10^{-5} M$ .

The results of the binding experiments are shown in Figures 3 and 4. It was previously reported<sup>9,10</sup> that  $T_3$ ,  $T_4$ , and other thyroid analogs bind to subcellular components: microsomes, mitochondria, soluble proteins, etc.  $T_3$  is bound to both microsomes (M) and soluble cellular proteins (E) of this system. The relative binding of the two fractions for  $T_3$  varies with the  $T_3$  concentration; for the microsomes, the per cent binding of the total <sup>131</sup>I- $T_3$  added to the enzymic system increases from 32% at  $4 \times 10^{-9}$  M to 61% at  $1 \times 10^{-3}$  M.

<sup>(5)</sup> N. L. R. Bucher and K. McGarrahan, J. Biel. Chem., 222, 1 (1956).

<sup>(6)</sup> J. H. Knauss, J. W. Porter, and G. Wasson, ibid., 234, 2835 (1959).

<sup>(7)</sup> J. J. Kabara, J. T. McLanghlin, and C. A. Riegel, Anal. Chem., 33, 305 (1961).

<sup>(8)</sup> C. D. Eskelson, Ph.D. Thesis, University of Nebraska, Lincoln. Neb., Jan 1967.

<sup>(9)</sup> J. R. Tata, L. Ernster and E. M. Saranyi, *Biochim. Biophys. Acta*, **60**, 480 (1962).

<sup>(10)</sup> J. B. Tata, L. Ernster, and E. M. Suranyi, *ibid.*, **60**, 461 (1962).




Figure 1.—The time course of <sup>14</sup>C-acetate incorporation into cholesterol and the effect of L-triiodothyronine on cholesterol synthesis. The ordinate represents corrected DPM observed in the isolated cholesterol tomatinide. Each point of the curves represents the average of four replicates  $\pm$  the standard deviation: control line ( $\phi$ ); T<sub>s</sub> line ( $\phi$ ).

whereas the percentage binding to the protein fraction decreases from 44% to 8% at the respective T<sub>3</sub> concentrations.

In this system most of the  $T_4$  binding sites on the soluble proteins are saturated at  $1 \times 10^{-3} M T_4$ , since the total  $T_4$  bound to the proteins drops off significantly at this hormone concentration. The data for  $T_4$  binding in Figure 4 are generally similar to those for the  $T_3$  binding curves.  $T_4$  binds to both microsomes and the soluble proteins, the degree of binding varying with the  $T_4$  concentration. However some differences are noted. At  $1.0 \times 10^{-5} M T_4$  and  $T_3$ , 30% of the  $T_4$ and 15% of the T<sub>3</sub> are bound to soluble protein, whereas 52% T<sub>4</sub> and 60% T<sub>3</sub> are bound to the microsomes, respectively. The binding of sodium radioidide to the soluble protein and microsomes was also studied in this system. At a NaI concentration of  $1.0 \times 10^{-3} M$ , 1.8% of radioiodide was bound to microsomes; 5.1%was bound to the soluble proteins; and 93.0% was found in the supernatant fluid. The high levels of binding of  $T_3$  and  $T_4$  to the microsomes plus the very low level of binding of radioiodide to the microsomes lends credence to the metabolic stability of the  $T_3$  and  $T_4$  in this system. Tata, et al.,<sup>9</sup> in their studies have shown by chromatography that 76-83% of the radioactivity present in the various subcellular components is undegraded  $T_3$  and  $T_4$ .

The 19 thyroid hormone analogs were tested in the standard system using <sup>14</sup>C-acetate as the precursor. These results are expressed in Table I. Also tested was the effect of  $T_3$ ,  $p-T_4$ , L-thyronine, and  $pL-T_3$  on cholesterolgenesis using <sup>14</sup>C-mevalonate as the precursor. Because of the limitations of the number of samples to be assayed, the testing had to be conducted in a series of four experiments. In each case a group of samples to which  $T_3$  was added was included to compare  $T_3$ 's action for that preparation with the other analogs. All precursors were tested at  $1.0 \times 10^{-4} M$  concentration. Experiment 1 indicates that the solvent, DMSO, used for dissolving the analogs enhances cholesterol synthesis from acetate but not from mevalonate. This

#### TABLE I

THE EFFECT OF VARIOUS THYROID ANALOGS

	оn <i>in Vitro</i> Сно	LESTEROL	GENESI	S <sup>a</sup>	
Group	Additions to the	From <sup>14</sup> C-acetate substrate, dpm ± std dev		From <sup>14</sup> C-mevalonate substrate, dpm ± std dev	
No.	enzymic system				
	E	pt 1			
1	Control	$2388^{b}$	$18_{-}$		
$^{2}$	0.2 ml of DMSO	4006°	180	18,977	895
3	L-T3	$2117^{d}$	186	18,872	507
4	D-T4	$2638^{d}$	915	18,717	739
5	L-Thyronine	5228	1318	19,428	937
6	DL-T3	1813 <sup>d</sup>	125	19,740	794
	E	pt 2			
1	Control	4121	400		
2	L-T3	30210	261		
3	3.5-Diiodo-3'-L-ethyl-	3786	793		
	thyronine				
4	3.5-Diiodo-3'-L-iso-	4105	593		
	propylthyronine				
5	3,5-Diiodo-3'-L-phenyl-	1930°	199		
	thyronine				
6	3.5-Diiodo-3'-L-iso-	4442	882		
-	butylthyronine	0000	105		
7	3,5-Diiodo-3'-1t-butyl-	3966	495		
	thyronine				
	E	xpt 3			
1	Control	3465	441		
2	L-T3	1633°	71		
3	3,5-Diiodothyronine	2861	374		
4	3-Iodothyronine	3760	396		
5	3,3',5'-Trichlorothyronine	3421	20		
6	3,3'-Dichlorothyronine	3152	344		
7	3-Chlorothyronine	3641	62		
8	Thyroxamine	3585	221		
9	Each of 3-iodothyronine	2661	184		
	and $L-T_3$				
	E	xpt 4			
1	Control	20,864	1549		
$^{2}$	T₃	18,1810	1002		
3	3,5,3',5'-Tetraiodothyro-	23,507	1525		
	propionic acid				
4	3,5,3′,5′-Tetraiodoformic acid	23,013	854		
ō	3,5,3'-Triiodothyro- propionic acid	22,125	788		
6	3,5,3'-Triiodothyro- acetic acid	23,221	1153		

<sup>a</sup> Nineteen analogs were tested in a series of four experiments. All analogs were added in 0.2 ml of DMSO solvent so that the final concentration was  $1.0 \times 10^{-4}M$ . The first four analogs listed in expt 1 were also tested in this system using "C-mevalonate as the precursor for cholesterol synthesis. <sup>b</sup> The results are expressed as the average of four replicates of the corrected dpm  $\pm$  the standard deviation of the isolated cholesterol tomatinide. <sup>c</sup> Significant from group 1. <sup>d</sup> Significant from group 2.

has been previously reported and observed faithfully for the system<sup>8</sup> (see Table I). As a consequence, all testing included a control group to which DMSO was added. All analogs added were dissolved in the same volume of DMSO (0.2 ml) as was added to the control. We have also observed the inhibition of  $T_3$  on cholesterol synthesis using acetate as precursor when aqueous solvents were used in the control and as the solvent vehicle for  $T_3$ .<sup>4</sup> The basal rate at which cholesterol synthesis proceeds in the standard system using <sup>14</sup>C-acetate as precursors varies with each preparation. The variability is known to be related in part to the nutritional status of the animals prior to sacrifice as well as to other factors of preparation of the enzyme extracts.<sup>5,6,8,11</sup>

Of the analogs tested, none affected synthesis of cholesterol from mevalonate. Whether this is true for

(11) T. A. Miettinen, J. Lab. Clin. Med., 71, 537 (1968).




Figure 2.—Effect of increasing concentration of  $T_x$  on cholesterolgenesis from acctate. Control line is the negative of the standard deviation from the control value (see arrow on ordinant). The control value and each point on the curve with added  $T_x(\varphi)$  represents the average of four replicates  $\pi$  standard deviation.

Figure 3.—Per cent of total  $\mathbb{P}^{34}$ labeled T<sub>b</sub> added to the enzymic system which is bound to microsomes  $\mathbb{P}_{2}$  and soluble protein ( $\square$ ) fractions. Each point represents the average of duplicate determinations. The total T<sub>a</sub> bound fraction is equal to the sum of the T<sub>a</sub> bound to protein and *v*aicrosomal fractions ( $\mathbb{O}$ ).

the other analogs, which were not tested, is not known.

Of the analogs tested,  $T_3$ ,  $DL-T_3$ ,  $D-T_4$ , and DL-3,5-diiodo-3'-phenylthyronine were effectively inhibiting chalesterol synthesis from acetate precursor.

Table II indicates the results of a study on the effect of adding both  $T_3$  and  $T_4$  at  $0.5 \times 10^{-4} M$  each as well as  $2.5 \times 10^{-6} M$  each. At the former concentration a significant inhibition of cholesterol synthesis is observed, indicating a synergism between the two compounds. It should be noted that  $T_3$  added at  $0.5 \times 10^{-4} M$  lowers cholesterolgenesis, but by our statistical analyses fails to record significance (*P*'s are for the 98% level).

The data in Table III indicate that  $D-T_4$  inhibits cholesterolgenesis significantly, whereas at the same concentration  $L-T_4$  does not. The data suggest that  $D-T_4$  is more effective than  $L-T_3$ , but the differences between these groups (3 and 4) are not significant. Once again a nonsignificant depression of synthesis is ob-

TABLE H

Synergym of 3.5,3'-Triodothyronine and Thyroxine on Cholesterolgenesis from <sup>14</sup>C-Acetaty

Group				
no.	Additions to the puzymic system	${ m Dpm}~\pm~{ m std}~{ m dev}$		
ł	Control	$1884^{\circ}$	323	
2	0.2 ml of DMSO	$3404^{6}$	1790	
з	$0.2~{ m nnl}$ of DMSO ${ m T_8}$ and ${ m T_4}$ each at	18f2*	1337	
	$0.5 \times 10^{-4} M$			
	$(1, 0) \rightarrow (1, 0, 1) \rightarrow (1, 0) $	413 (3)	-0-20	

 $\begin{array}{rrr} 4 & 0.2 \mbox{ nd of DMSO } T_{a} \mbox{ and } T_{4} \mbox{ each at } & 4042 & 239 \\ & 2.5 \times 10^{-c} M \end{array}$ 

<sup>o</sup> The results are expressed as the average of four replicates of the corrected dpm  $\pm$  the standard deviation of isolated cholesterol tomatinide. <sup>b</sup> Significant from group 1. <sup>c</sup> Significant from group 2.

served when L-T<sub>c</sub> is used at  $1.0 \times 10^{-4} M$ . At higher concentrations L-T<sub>c</sub> inhibits this system.<sup>4</sup>

It is conceivable that many of the thyroid analogs tested here could have an effect on the cholesterolgenic




Figure 4.—Binding of <sup>131</sup>I-labeled T4 to the microsomes ( $\triangle$ ) and soluble protein fractions ( $\square$ ). Conditions were the same as for Figure 3.

TABLE III Comparison of the Effects of  $L-T_3$ ,  $L-T_4$ , and  $D-T_4$  on Cholesterolgenesis from <sup>14</sup>C-Acetate

D-14 ON CHOLESTEROLGENESIS FROM "C-ACETATE					
Group no.	Additions to the enzymic system	Expt		Exp dpm ±	
1	0.2  ml of DMSO	$2249^{\circ}$	325	5526	1317
2	Control 0.2 ml of DMSO $1.0 \times 10^{-4}M$				
	L-T <sub>4</sub>	1824	17\$	4290	526
3	0.2  ml of DMSO $1.0  imes 10^{-4}M$				
	$D-T_4$	$846^{b}$	307	$2348^{\circ}$	553
4	0.2 ml of DMSO				
	$1.0 imes10^{-4}M$	$1185^{b}$	126	$2976^{3}$	643
	$L-T_3$				

<sup>a</sup> The results are expressed as the average of four replicates of the corrected dpm  $\pm$  the standard deviation of isolated cholesterol tomatinide. <sup>b</sup> Significant from groups 1 and 2.

system. For example, the possibility exists that if they were more avidly bound to inert proteins than  $T_3$ or  $T_4$  their influences would not be elicited at the hormone concentrations studied here.

The data for the pretreatment of the enzymic system with  $T_3$  and  $T_4$  followed by separation and recombination are shown in Table IV. The enzymic activity of the reconstituted system is severely depressed. This may be due to the various manipulative stages involved. The isolated microsomes are sticky and difficult to resuspend, and were subjected to considerable trauma. It is known that simply overhomogenizing the initial preparation leads to loss of activity<sup>6</sup> suggesting that the integrity of the microsomal structure is an important consideration for an active preparation.

In all cases pretreatment of either or both fractions with  $T_3$  or  $T_4$  leads to significant lowering of cholesterol formation. It was not possible to discern whether pretreating the microsomes alone with either  $T_3$  or  $T_4$ was more effective in lowering cholesterol formation than with pretreatment of the E fraction. The data

 $TABLE \ IV$  The Effect on Cholesterol Biosynthesis of Pretreating Microsomes or Soluble Proteins with T3 or T4

Group	Pretreatment of microsomes		
no.	and/or soluble enzymes	dpm $\pm$	std dev
1	$M^a + E^b$	262°	40
2	$M + E_{T_3}^d$	$176^{f}$	28
3	$M + E_{T_4}^e$	$172^{f}$	50
4	$M_{T_3}^{\rho} + E_{T_3}$	$106^{f,h}$	17
ō	$M_{T_3} + E_{T_4}$	$100^{h,i}$	9
6	$M_{T_3} + E$	122'	32
7	$M_{T_4}{}^j + E_{T_3}$	109'	23
8	$M_{T_4} + E_{T_4}$	105'	34
9	$M_{T_4} + E$	1001	27
			\ <b>-</b>

<sup>a</sup> M (Microsomes). <sup>b</sup> E (soluble cellular enzymes). <sup>c</sup> Each value represents the mean of four replicate determinations, except for group 1, of the corrected dpm  $\pm$  the standard deviation of the isolated cholesterol tomatinide. Group 1 was replicated ten times. <sup>d</sup> E<sub>T3</sub> (soluble cellular enzymes pretreated with T<sub>3</sub>). <sup>e</sup> E<sub>T4</sub> (soluble cellular enzymes pretreated with T<sub>4</sub>). <sup>f</sup> Significant from 1. <sup>e</sup> M<sub>T3</sub> (microsomes pretreated with T<sub>5</sub>). <sup>h</sup> Significant from 3. <sup>i</sup> M<sub>T4</sub> (microsomes pretreated with T<sub>4</sub>).

suggest that this is true, but significance at 98% level was not achieved. Pretreatment and combination of both fractions appear to inhibit maximally, especially when the microsomes had been pretreated with  $T_3$ (groups 4 and 5). Undoubtedly the reconstituted systems undergo a reequilibration of the  $T_3$  and  $T_4$  for the various binding sites on both the microsomes and protein fraction. The data suggest that the inhibition observed with pretreated E fractions (groups 2 and 3) may be due to reassociation with the untreated microsomes by the  $T_3$  or  $T_4$  bound to the E fraction. The reverse may also be true (groups 6 and 9) but the indication is that the microsomes bind  $T_3$  and  $T_4$  more firmly than does the E fraction (Figure 4).

# Discussion

The rate-determining step of cholesterolgenesis occurs in the microsomes and is concerned with the reduction of HMG-coenzyme A to form mevalonic acid.<sup>12</sup> When mevalonic acid is used as substrate, the rate-determining cholesterolgenic reaction is bypassed. The results in Table I, expt 1, indicate that the thyroid hormones are influencing cholesterolgenesis from <sup>14</sup>C-acetate and not from <sup>14</sup>C-mevalonate. This suggests that the ratedetermining reaction for cholesterolgenesis is under thyroid hormone influence. This concept is further supported by the data recorded in Table IV in which microsomes exposed to  $T_3$  or  $T_4$  have the lowest ability for cholesterolgenesis. The studies of l'letcher and Myant<sup>13</sup> using liver homogenates from rats pretreated with high levels of  $T_4$  also support these concepts. The decreased cholesterolgenesis observed (see Table IV) when microsomes are incubated with soluble enzymes which were exposed to the thyroid hormones is probably a reflection of the transference of  $T_3$  or  $T_1$  due to binding competition (see Figures 3 and 4) between the cell sap proteins and microsomal proteins.

The rate of cholesterolgenesis is decreased by  $T_3$  and is proportional to the amount of  $T_3$  present in the *in* vitro system (see Figures 1 and 2). The high concentrations of the thyroid hormones necessary to elicit the response in this system certainly suggest pharmacological levels are necessary, and may be necessary because of a nonspecific binding of  $T_3$  and  $T_4$  to inert proteins, effectively removing them from the active sites on the cholesterolgenic enzymes (see Figures 3 and 4). Since " $T_3$  and  $T_4$  activity" resides in the microsomes (see Table IV), and from the data in Figures 3 and 4 it may be concluded that either  $T_3$  is twice as effective as  $T_4$  in decreasing cholesterolgenesis or that twice as many  $T_4$  binding sites exist on the microsomes.

Many of the binding sites for  $T_3$  and  $T_4$  are identical as illustrated in Table III in which a synergistic action between  $T_3$  and  $T_4$  is demonstrated. Since  $T_4$  seems more avidly bound by the system it may be suggested that  $T_4$  is occupying some of the binding sites of  $T_3$ , thus freeing  $T_3$  to react with enzymes being influenced by the thyroid hormone. 3-Iodothyronine does not seem to bind the proteins of the system as does  $T_4$  (see Table I, expt 3, group 9), since no synergism is elicited between 3-iodothyronine and  $T_3$ .

Specific structural requirements seem necessary for the action elicited by the thyroid hormones. The carboxyl group is essential since thyroxamine does not elicit a response. The carboxyl group must be  $\alpha$  to an amino group since 3,5,3'-triiodothyropropionic acid does not elicit a response (see Table I, expt 3 and 4). The b isomer appears more active than the L isomer and may be explained on the basis that it does not bind to proteins or subcellular particles<sup>10</sup> as much as the L-isomer (see Tables I and III, expt 1). Evidence suggests that the 3.5-diiodo groups are not necessary; however, the 3'-iodo group or a similar bulky constituent whose molecular weight is greater than 77, *i.e.*, Ph. is essential for inhibitory cholesterolgenic activity (see Table I). The PhO grouping is at least spatially essential since diiodotyrosine is not active in the system.<sup>4</sup> From the data presented here it may be postulated that the most active anticholesterolgenic compound would be a p-3'-iodo- (or bulky constituen() thyronine. It is suggested that the enzyme which is affected by  $T_3$  or  $T_4$  binds the hormone at three points, *i.e.* carboxyl group, amino group, and 3'-iodo group.

Attempts to demonstrate altered microsomal structure by thyroid hormones, using the methods of Tedeschi, *et al.*,<sup>14</sup> have failed to indicate this process occurs as suggested earlier.<sup>4</sup>

It is probable that the HMG-CoA reductase is being inhibited by these hormones. This possibility is interesting since HMG-CoA reductase synthesis seems to be controlled by the thyroid hormones.<sup>2,3</sup> These facts are significant in that the influenced enzyme is rate determining<sup>12</sup> and catalyzes an irreversible reaction. It is conceivable therefore, if the HMG-CoA reductase activity was not controlled and the enzyme concentration increased, that many metabolic processes would decrease due to the shunting of acetyl-CoA from the general body pool. An important principle may be implicated here, since an enzyme whose synthesis requires a small amount of the hormone's presence may also have its activity controlled by larger amounts of the same hormone. In the case of the thyroid hormones indications are that various protein binding sites must be filled, and thus greater concentrations of hormone are needed, before the hormone elicits an inhibition on the active enzyme.

Acknowledgments.—We are deeply indebted to Drs. Benjamin Blank of Smith Kline and French Laboratories, Paul Block, Jr., River Research, Toledo, Ohio, and Lee N.Starker, Morris Plains, N. J., for supplying us with most of the thyroid analogs. Much thanks are extended to Mr. Fernando Moreno and Mrs. Glenda Butterfield for their excellent technical assistance. We wish to thank Mrs. Helen Tesarch at the Omaha Veterans Administration Hospital Computer Center for running the statistical analyses on these data.

<sup>(12)</sup> N. L. R. Bucher, K. McGarraban, E. Gould, and A. V. Lond, J. Biol. Chem., 234, 262 (1959).

<sup>(13)</sup> K. Fletcher and N. B. Myant, Physiology, 154, 15 (1960).

<sup>(14)</sup> II. Tedeselő, J. M. James, and W. Anthony, J. Cell Biol.,  ${\bf 18},$  503 (1963).